Evidence map›Paper›PMID 28222785›Full record

ArticleJournal of translational medicine2017

TCD4

Andrea Picchianti Diamanti, Bruno Laganà, Maria Christina Cox, Emanuela Pilozzi, Rachele Amodeo, Maurizio Bove, Milica Markovic, Roberta Di Rosa, Simonetta Salemi, Maria Laura Sorgi and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Andrea Picchianti DiamantiDepartment of Clinical and Molecular Medicine, S. Andrea University Hospital, School of Medicine and Psychology, "Sapienza" University, Via di Grottarossa 1039, 00189, Rome, Italy. andrea.picchiantidiamanti@uniroma1.it.ORCID 0000-0002-8552-4641
Bruno LaganàDepartment of Clinical and Molecular Medicine, S. Andrea University Hospital, School of Medicine and Psychology, "Sapienza" University, Via di Grottarossa 1039, 00189, Rome, Italy.
Maria Christina CoxHaematology Unit, Rome, Italy.
Emanuela PilozziUOC Anatomic Pathology, Rome, Italy.
Rachele AmodeoUOC Laboratory Diagnostic, Rome, Italy.
Maurizio BoveUOC Laboratory Diagnostic, Rome, Italy.
Milica MarkovicDepartment of Clinical and Molecular Medicine, S. Andrea University Hospital, School of Medicine and Psychology, "Sapienza" University, Via di Grottarossa 1039, 00189, Rome, Italy.
Roberta Di RosaDepartment of Clinical and Molecular Medicine, S. Andrea University Hospital, School of Medicine and Psychology, "Sapienza" University, Via di Grottarossa 1039, 00189, Rome, Italy.
Simonetta SalemiDepartment of Clinical and Molecular Medicine, S. Andrea University Hospital, School of Medicine and Psychology, "Sapienza" University, Via di Grottarossa 1039, 00189, Rome, Italy.
Maria Laura SorgiDepartment of Clinical and Molecular Medicine, S. Andrea University Hospital, School of Medicine and Psychology, "Sapienza" University, Via di Grottarossa 1039, 00189, Rome, Italy.
Maria Manuela RosadoMenarini Group, Research Toxicology Center (R.T.C), Pomezia, Italy.
Raffaele D'AmelioDepartment of Clinical and Molecular Medicine, S. Andrea University Hospital, School of Medicine and Psychology, "Sapienza" University, Via di Grottarossa 1039, 00189, Rome, Italy.
Sapienza University of Rome · ITAzienda Ospedaliera Sant'Andrea · ITMenarini Group (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLymphocyte expansion and true lymphocytosis are commonly observed in the everyday clinical practice. The meaning of such phenomenon is often poorly understood so that discrimination between benign and malignant lymphocytosis remains difficult to establish. This is mainly true when lymphocytosis rises in patients affected by immune-mediated chronic inflammatory diseases under immunosuppressive treatment, conditions potentially associated with lymphomagenesis. In this brief report the development of mild T CD4

methodsTwo hundred eight rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients have been evaluated longitudinally for at least 1-year before and 2-years after anti-TNF-α therapy introduction for the possible appearance of a lymphocyte expansion. In patients who developed lymphocyte expansion, T, B and NK cells were analysed.

resultsTwenty-five out of 208 (12%) subjects developed a mild T CD4

conclusionsThis is the first longitudinal cohort study evaluating the onset of lymphocytosis in RA and PsA patients under anti-TNF-α treatment and its possible clinical relevance. A mild T CD4

Indexed as

Antirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidCD4 AntigensDemographyFemaleHumansLymphocyte CountLymphocytosisMaleMiddle AgedT-LymphocytesTumor Necrosis Factor-alphaAntirheumatic AgentsCD4 AntigensTumor Necrosis Factor-alphaAnti-TNF-α agentLymphocytosisPsoriatic arthritisRheumatoid arthritisTCR

Identifiers

PMID28222785
PMCPMC5322781
OpenAlexW2589640024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.